Clinical Trials Browser

Completed × Leukemia, Biphenotypic, Acute × blinatumomab × Clear all

NCT04827745 2025-07-03

Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL

Phase 2 Completed

Other hematologic neoplasm

Leukemia, Biphenotypic, Acute, Neoplasm, Residual